Rev Bras Oftalmol.2025;84:e0025
Xen® Gel Stent as a surgical option for glaucoma secondary to iridocorneal endothelial syndrome refractory to medical treatment
DOI: 10.37039/1982.8551.20250025
ABSTRACT
Our objective was to report the case of the use of Xen® Gel Stent in the surgical treatment of glaucoma secondary to iridocorneal endothelial syndrome. Female patient, 38 years old, with unilateral glaucoma secondary to iridocorneal endothelial syndrome in the right eye, using maximum tolerable medications (three medications), with medicated intraocular pressure oscillating between 16 and 18 mmHg, demonstrating structural and functional progression, underwent minimally invasive bleb surgery with ab interno closed-conjunctival implantation of a Xen® Gel Stent. The surgery occurred without complications and the postoperative evolution has been favorable for up to 12 months, with intraocular pressure varying from 8 to 12 mmHg, without hypotensive medications and without complications or reinterventions. The Xen® Gel Stent implant provided good intraocular pressure control in the intermediate term with an excellent safety profile. It opens a perspective for new studies of the use of these devices in cases of glaucoma secondary to iridocorneal endothelial syndrome refractory to medical treatment.
